港股异动 | 宜明昂科-B大涨8%！已向CDE提交IMM2510的III期临床试验申请

智通财经10-03

智通财经APP获悉，宜明昂科-B(01541)再涨超8%、五日累涨38%。消息面上，宜明昂科昨日发布公告称，集团已向国家药品监督管理局药品审评中心提交IMM2510用于治疗经免疫治疗(IO)耐药性非小细胞肺癌(NSCLC)的III期临床试验的申请，并于近期递交两项针对不同类型肺癌的III期注册临床试验。此外，国元国际近期研报指出，公司研发管线不断丰富，抗风险能力提升，CD47CD20双抗（...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

章鱼888
10-03
章鱼888
别管，反正要起飞
天才1207
10-03
天才1207
说说你对这篇新闻的看法...

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2572572094?lang=zh_CN&edition=full","thumbnail":"https://community-static.tradeup.com/news/86700e5998d8a25a4fe570ae31b092f1","is_english":false,"pubTime":"2025-10-03 15:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2572572094","market":"hk","top_or_hot":-1,"title":"港股异动 | 宜明昂科-B大涨8%！已向CDE提交IMM2510的III期临床试验申请","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，宜明昂科-B(01541)再涨超8%、五日累涨38%。消息面上，宜明昂科昨日发布公告称，集团已向国家药品监督管理局药品审评中心提交IMM2510用于治疗经免疫治疗(IO)耐药性非小细胞肺癌(NSCLC)的III期临床试验的申请，并于近期递交两项针对不同类型肺癌的III期注册临床试验。此外，国元国际近期研报指出，公司研发管线不断丰富，抗风险能力提升，CD47CD20双抗（...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1352101.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 宜明昂科-B大涨8%！已向CDE提交IMM2510的III期临床试验申请</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 宜明昂科-B大涨8%！已向CDE提交IMM2510的III期临床试验申请\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-03 15:31 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1352101.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，宜明昂科-B(01541)再涨超8%、五日累涨38%。消息面上，宜明昂科昨日发布公告称，集团已向国家药品监督管理局药品审评中心提交IMM2510用于治疗经免疫治疗(IO)耐药性非小细胞肺癌(NSCLC)的III期临床试验的申请，并于近期递交两项针对不同类型肺癌的III期注册临床试验。此外，国元国际近期研报指出，公司研发管线不断丰富，抗风险能力提升，CD47CD20双抗（...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1352101.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1223083913.SGD","symbol_name":"Schroder ISF Global Gold A Acc SGD-H","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1352101.html","article_id":"2572572094","we_media_id":null,"thumbnails":["https://community-static.tradeup.com/news/86700e5998d8a25a4fe570ae31b092f1"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2572572094","pubTimestamp":1759476661,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，宜明昂科-B(01541)再涨超6%，截至发稿，涨6.69%，报15.15港元，成交额4567.05万港元。消息面上，宜明昂科昨日发布公告称，集团已向国家药品监督管理局药品审评中心提交IMM2510用于治疗经免疫治疗(IO)耐药性非小细胞肺癌(NSCLC)的III期临床试验的申请，并于近期递交两项针对不同类型肺癌的III期注册临床试验。此外，国元国际近期研报指出，公司研发管线不断丰富，抗风险能力提升，CD47CD20双抗（IMM0306）临床疗效数据优秀，有望成为自免领域重磅药物。公司是CD47融合蛋白全球创新引领者，管线丰富，在肿瘤及自免领域应用前景广阔。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1223083913.SGD":"Schroder ISF Global Gold A Acc SGD-H","BK4017":"黄金","BK4134":"信息科技咨询与其它服务","LU1223082519.USD":"SCHRODER ISF GLOBAL GOLD \"A\" (USD) INC AV","01541":"宜明昂科-B","LU1223082196.USD":"施罗德环球黄金A Acc","BK4614":"Manus概念股","BK1161":"生物科技"},"translate_title":"Changes in Hong Kong stocks | Yi Ming Angke-B soared 8%! Phase III clinical trial application for IMM2510 has been submitted to CDE","themeId":"4fffb731420a714b5e960cfdb4214349","isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/b94298a8388dbd8f2717b803e2241110","symbols_score_info":{"01541":1.1},"content_text":"智通财经APP获悉，宜明昂科-B(01541)再涨超8%、五日累涨38%。消息面上，宜明昂科昨日发布公告称，集团已向国家药品监督管理局药品审评中心提交IMM2510用于治疗经免疫治疗(IO)耐药性非小细胞肺癌(NSCLC)的III期临床试验的申请，并于近期递交两项针对不同类型肺癌的III期注册临床试验。此外，国元国际近期研报指出，公司研发管线不断丰富，抗风险能力提升，CD47CD20双抗（IMM0306）临床疗效数据优秀，有望成为自免领域重磅药物。公司是CD47融合蛋白全球创新引领者，管线丰富，在肿瘤及自免领域应用前景广阔。","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[{"id":485203186675768,"gmtCreate":1759487002271,"gmtModify":1759487004574,"author":{"id":"4203498746370332","authorId":"4203498746370332","name":"章鱼888","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"authorIdStr":"4203498746370332","idStr":"4203498746370332"},"htmlText":"别管，反正要起飞","listText":"别管，反正要起飞","text":"别管，反正要起飞","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/485203186675768","repostId":2572572094,"repostType":2,"repost":{"id":"2572572094","kind":"news","pubTimestamp":1759476661,"share":"https://www.laohu8.com/m/news/2572572094?lang=&edition=full","pubTime":"2025-10-03 15:31","market":"hk","language":"zh","title":"港股异动 | 宜明昂科-B大涨8%！已向CDE提交IMM2510的III期临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2572572094","media":"智通财经","summary":"智通财经APP获悉，宜明昂科-B(01541)再涨超6%，截至发稿，涨6.69%，报15.15港元，成交额4567.05万港元。消息面上，宜明昂科昨日发布公告称，集团已向国家药品监督管理局药品审评中心提交IMM2510用于治疗经免疫治疗(IO)耐药性非小细胞肺癌(NSCLC)的III期临床试验的申请，并于近期递交两项针对不同类型肺癌的III期注册临床试验。此外，国元国际近期研报指出，公司研发管线不断丰富，抗风险能力提升，CD47CD20双抗（IMM0306）临床疗效数据优秀，有望成为自免领域重磅药物。公司是CD47融合蛋白全球创新引领者，管线丰富，在肿瘤及自免领域应用前景广阔。","content":"<html><head></head><body><p>智通财经APP获悉，<a href=\"https://laohu8.com/S/01541\">宜明昂科-B</a>(01541)再涨超8%、五日累涨38%。</p><p></p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/1a163769f260eb9f5d2ff68b91dac308\" title=\"\" tg-width=\"560\" tg-height=\"240\"/></p><p>消息面上，宜明<a href=\"https://laohu8.com/S/02216\">昂科</a>昨日发布公告称，集团已向国家药品监督管理局药品审评中心提交IMM2510用于治疗经免疫治疗(IO)耐药性非小细胞肺癌(NSCLC)的III期临床试验的申请，并于近期递交两项针对不同类型肺癌的III期注册临床试验。</p><p>此外，国元国际近期研报指出，公司研发管线不断丰富，抗风险能力提升，CD47CD20双抗（IMM0306）临床疗效数据优秀，有望成为自免领域重磅药物。公司是CD47融合蛋白全球创新引领者，管线丰富，在肿瘤及自免领域应用前景广阔。</p></body></html>","source":"stock_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 宜明昂科-B大涨8%！已向CDE提交IMM2510的III期临床试验申请</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 宜明昂科-B大涨8%！已向CDE提交IMM2510的III期临床试验申请\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-03 15:31 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1352101.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，宜明昂科-B(01541)再涨超8%、五日累涨38%。消息面上，宜明昂科昨日发布公告称，集团已向国家药品监督管理局药品审评中心提交IMM2510用于治疗经免疫治疗(IO)耐药性非小细胞肺癌(NSCLC)的III期临床试验的申请，并于近期递交两项针对不同类型肺癌的III期注册临床试验。此外，国元国际近期研报指出，公司研发管线不断丰富，抗风险能力提升，CD47CD20双抗（...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1352101.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://community-static.tradeup.com/news/86700e5998d8a25a4fe570ae31b092f1","relate_stocks":{"LU1223083913.SGD":"Schroder ISF Global Gold A Acc SGD-H","BK4017":"黄金","BK4134":"信息科技咨询与其它服务","LU1223082519.USD":"SCHRODER ISF GLOBAL GOLD \"A\" (USD) INC AV","01541":"宜明昂科-B","LU1223082196.USD":"施罗德环球黄金A Acc","BK4614":"Manus概念股","BK1161":"生物科技"},"source_url":"http://www.zhitongcaijing.com/content/detail/1352101.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2572572094","content_text":"智通财经APP获悉，宜明昂科-B(01541)再涨超8%、五日累涨38%。消息面上，宜明昂科昨日发布公告称，集团已向国家药品监督管理局药品审评中心提交IMM2510用于治疗经免疫治疗(IO)耐药性非小细胞肺癌(NSCLC)的III期临床试验的申请，并于近期递交两项针对不同类型肺癌的III期注册临床试验。此外，国元国际近期研报指出，公司研发管线不断丰富，抗风险能力提升，CD47CD20双抗（IMM0306）临床疗效数据优秀，有望成为自免领域重磅药物。公司是CD47融合蛋白全球创新引领者，管线丰富，在肿瘤及自免领域应用前景广阔。","news_type":1,"symbols_score_info":{"01541":1.1}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":485164428165568,"gmtCreate":1759477442016,"gmtModify":1759478277605,"author":{"id":"4213755732132142","authorId":"4213755732132142","name":"天才1207","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"4213755732132142","idStr":"4213755732132142"},"htmlText":"说说你对这篇新闻的看法...","listText":"说说你对这篇新闻的看法...","text":"说说你对这篇新闻的看法...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/485164428165568","repostId":2572572094,"repostType":2,"repost":{"id":"2572572094","kind":"news","pubTimestamp":1759476661,"share":"https://www.laohu8.com/m/news/2572572094?lang=&edition=full","pubTime":"2025-10-03 15:31","market":"hk","language":"zh","title":"港股异动 | 宜明昂科-B大涨8%！已向CDE提交IMM2510的III期临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2572572094","media":"智通财经","summary":"智通财经APP获悉，宜明昂科-B(01541)再涨超6%，截至发稿，涨6.69%，报15.15港元，成交额4567.05万港元。消息面上，宜明昂科昨日发布公告称，集团已向国家药品监督管理局药品审评中心提交IMM2510用于治疗经免疫治疗(IO)耐药性非小细胞肺癌(NSCLC)的III期临床试验的申请，并于近期递交两项针对不同类型肺癌的III期注册临床试验。此外，国元国际近期研报指出，公司研发管线不断丰富，抗风险能力提升，CD47CD20双抗（IMM0306）临床疗效数据优秀，有望成为自免领域重磅药物。公司是CD47融合蛋白全球创新引领者，管线丰富，在肿瘤及自免领域应用前景广阔。","content":"<html><head></head><body><p>智通财经APP获悉，<a href=\"https://laohu8.com/S/01541\">宜明昂科-B</a>(01541)再涨超8%、五日累涨38%。</p><p></p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/1a163769f260eb9f5d2ff68b91dac308\" title=\"\" tg-width=\"560\" tg-height=\"240\"/></p><p>消息面上，宜明<a href=\"https://laohu8.com/S/02216\">昂科</a>昨日发布公告称，集团已向国家药品监督管理局药品审评中心提交IMM2510用于治疗经免疫治疗(IO)耐药性非小细胞肺癌(NSCLC)的III期临床试验的申请，并于近期递交两项针对不同类型肺癌的III期注册临床试验。</p><p>此外，国元国际近期研报指出，公司研发管线不断丰富，抗风险能力提升，CD47CD20双抗（IMM0306）临床疗效数据优秀，有望成为自免领域重磅药物。公司是CD47融合蛋白全球创新引领者，管线丰富，在肿瘤及自免领域应用前景广阔。</p></body></html>","source":"stock_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 宜明昂科-B大涨8%！已向CDE提交IMM2510的III期临床试验申请</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 宜明昂科-B大涨8%！已向CDE提交IMM2510的III期临床试验申请\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-03 15:31 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1352101.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，宜明昂科-B(01541)再涨超8%、五日累涨38%。消息面上，宜明昂科昨日发布公告称，集团已向国家药品监督管理局药品审评中心提交IMM2510用于治疗经免疫治疗(IO)耐药性非小细胞肺癌(NSCLC)的III期临床试验的申请，并于近期递交两项针对不同类型肺癌的III期注册临床试验。此外，国元国际近期研报指出，公司研发管线不断丰富，抗风险能力提升，CD47CD20双抗（...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1352101.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://community-static.tradeup.com/news/86700e5998d8a25a4fe570ae31b092f1","relate_stocks":{"LU1223083913.SGD":"Schroder ISF Global Gold A Acc SGD-H","BK4017":"黄金","BK4134":"信息科技咨询与其它服务","LU1223082519.USD":"SCHRODER ISF GLOBAL GOLD \"A\" (USD) INC AV","01541":"宜明昂科-B","LU1223082196.USD":"施罗德环球黄金A Acc","BK4614":"Manus概念股","BK1161":"生物科技"},"source_url":"http://www.zhitongcaijing.com/content/detail/1352101.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2572572094","content_text":"智通财经APP获悉，宜明昂科-B(01541)再涨超8%、五日累涨38%。消息面上，宜明昂科昨日发布公告称，集团已向国家药品监督管理局药品审评中心提交IMM2510用于治疗经免疫治疗(IO)耐药性非小细胞肺癌(NSCLC)的III期临床试验的申请，并于近期递交两项针对不同类型肺癌的III期注册临床试验。此外，国元国际近期研报指出，公司研发管线不断丰富，抗风险能力提升，CD47CD20双抗（IMM0306）临床疗效数据优秀，有望成为自免领域重磅药物。公司是CD47融合蛋白全球创新引领者，管线丰富，在肿瘤及自免领域应用前景广阔。","news_type":1,"symbols_score_info":{"01541":1.1}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":1,"commentSize":2,"repostSize":2,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2572572094","isCrawlerRequest":true}